A novel formula to improve the accuracy and prognostic ability of determining the survival time after recurrent breast cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Prognosis for recurrent breast cancer (BC) has improved since 2012. Disease-free interval (DFI) and biomarkers like Ki-67 and HER2 status significantly correlate with survival time after recurrence (STR), aiding treatment decisions.
Area Of Science
- Oncology
- Biomarker Research
- Clinical Prognostics
Background
- Recurrent breast cancer (BC) presents a significant challenge with poor prognosis.
- Accurate assessment of survival time after recurrence (STR) is crucial for optimizing quality of life and guiding treatment strategies.
- This study investigates the predictive value of disease-free interval (DFI) and specific biomarkers for STR.
Purpose Of The Study
- To evaluate the impact of biomarkers on prognosis in recurrent breast cancer.
- To determine if DFI and biomarkers can effectively predict STR.
- To identify trends in BC recurrence prognosis over time.
Main Methods
- Analysis of 1,254 recurrent BC cases from January 2000 to December 2023.
- Stratification of cases into four time-based groups (2000-2005, 2006-2011, 2012-2017, 2018-2023).
- Application of simple linear regression and multivariate analysis to assess relationships between STR, DFI, and biomarkers (Ki-67, ER, HER2).
Main Results
- Significant improvement in survival rates after recurrence observed from 2012 onwards.
- No survival improvement noted for cases with HER2-0 status and Ki-67 index < 15%.
- Multivariate analysis identified Ki-67 as a significant factor in the 2000-2005 group, while ER and HER2 status became significant after 2012. Strong correlations between DFI and STR were found in deceased patients with Ki-67 > 30% and HER2-low status.
Conclusions
- Prognosis for recurrent breast cancer has demonstrably improved since 2012.
- DFI and specific biomarkers (Ki-67 > 30%, HER2-low) are strong predictors of STR in deceased patients.
- A predictive formula for STR was developed, requiring further clinical validation.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
Survival Times Are Positively Skewed
Survival times often exhibit positive skewness, unlike the normal distribution assumed...